Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study

Background: Checkpoint inhibitor immunotherapy or immuno-oncology (IO) treatment in refractory cervical cancer yielded an objective response rate (ORR) of 12% in tumors expressing the programmed cell death ligand-1 (PD-L1) in the KEYNOTE-158 phase II study. We hypothesized that the positive response...

Full description

Bibliographic Details
Main Authors: Kevin R. Shieh, Anna Huang, Yiqing Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
cervical cancer
immunotherapy
checkpoint inhibitor
PD-L1
tumor mutation burden
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.669587/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.669587/full

Similar Items